This clinical trial is focused on studying a condition known as pulmonary arterial hypertension (PAH). PAH is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. The study is evaluating a treatment called Ralinepag, which is taken as a prolonged-release tablet. This means the medication is designed to release slowly into the body over time. The purpose of the study is to understand how effective and safe Ralinepag is in improving treatment outcomes for patients with PAH.
Participants in the study will be randomly assigned to receive either Ralinepag or a placebo, which looks like the medication but does not contain the active substance. The study will monitor the time it takes for participants to experience a worsening of their condition, as defined by the study’s guidelines. This will help researchers determine the effectiveness of Ralinepag in delaying the progression of PAH. The study will also look at other factors, such as changes in exercise capacity and overall health status, to gather comprehensive data on the treatment’s impact.
The study will last for a period of up to 48 weeks, during which participants will have regular check-ups and assessments to track their health and any changes in their condition. This will include various tests and evaluations to ensure the safety and effectiveness of the treatment. The information gathered from this study will contribute to a better understanding of how Ralinepag can be used to manage PAH and improve the quality of life for those affected by this condition.
Austria 
Belgium 
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Portugal 
Romania 
Spain 
The Netherlands